clinical trial designThe PI3K–AKT–mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may there...
2.Seeking alpha in PI3K inhibition. 3.Pi3K inhibitors as new cancer therapeutics: implications for clinicaltrial design. 4.Novel Molecular-targeted Antitumor Drugs-PI3K Inhibitor. 2018年8月全球批准新药概况 乳腺癌最有潜力靶点——CDK4/6抑制剂盘点与解析 药渡...
8. Jiang B, Qi J, Song Y, Li Z, Tu M, Ping L, Liu Z, Bao H, Xu Z, Qiu L. Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies. J Hematol Oncol. 2021 Aug 23;14(1):130...
2.Seeking alpha in PI3K inhibition. 3.Pi3K inhibitors as new cancer therapeutics: implications for clinicaltrial design. 4.Novel Molecular-targeted Antitumor Drugs-PI3K Inhibitor.
Table 3 Drugs targeting PI3K in clinical trial Full size table Fig. 2 Targeting PI3K/Akt/mTOR pathway in cancer Full size image Dual PI3K/mTOR inhibitors NVP-BEZ235 (Dactolisib) NVP BEZ235 (dactolisib) is a dual PI3K/mTOR inhibitor and is currently in Phase I/II clinical trials. It ...
7. Zhiming Li, et al. Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma.Blood. Volume 138, Supplement 1, 23 November 2021, Page 2483.
signals enhance BCR signaling and generate therapeutic resistance toward Bcl-2 inhibitors.46,57Since these pathways exhibit only partial PI3Kδ dependency7use of an additional JAK:STAT inhibitor may further enhance the efficacy of PI3Kδ:Bcl-2 inhibitor combinations and provide a curative treatment ...
“The oral PI3Kδinhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial”(口服PI3Kδ抑制剂林普利塞治疗复发和/或难治滤泡性淋巴瘤:一项2期、单臂、开放标签临床研究)为题发表于《Clinical Cancer Research》(临床癌症...
(PTEN)13. Selective targeting PI3Kα has emerged as a promising approach for treatment of ESCC. Alpelisib, a PI3Kα-specific inhibitor, is currently in clinical trials to treat ESCC patients (NCT03292250 and NCT01822613)19. However, in the first-in-human clinical trial of alpelisib in solid ...
6. ZhimingLi, et al. Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma.Blood. Volume 138, Supplement 1, 23 November 2021...